Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria

This is the pre-peer reviewed version of the following article: urto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G. et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticarial. Br J Dermatol. 2018 Jul;179(1):210-212., which has been published in final form at http://dx.doi.org/10.1111/bjd.16379. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. info:eu-repo/semantics/openAccess ;ISSN: 0007-0963 ;EISSN: 1365-2133 ;DOI: 10.1111/bjd.16379

Digital Resources/Online E-Resources